Globalseo is still translating this page... (closing in 5s)
Skip to main content
cancer and weight

Mounjaro price rise leaves UK patients facing big bills

If you buy the weight-loss medicine Mounjaro privately in the UK you may see a steep price increase from September. The change will not affect you if you get your medicine from the NHS.

Here we show what are the alternatives and what you need to think about if you change or stop taking medicines.

What is Mounjaro and who uses it?

Mounjaro is the brand name for tirzepatide, a medicine that mimics hormones in your body to help control blood sugar and reduce appetite. It’s given by weekly injection and is licensed for type 2 diabetes and for weight loss and weight management in adults aged 18 and over.

Mounjaro is authorised for adult patients with a BMI of 30 or more (obesity), as well as those with a BMI between 27-30 (overweight) who also have weight-related health problems such as prediabetes, high blood pressure, high cholesterol, or heart problems.

At the moment, more than 1.5 million people in the UK use weight-loss medicines. Mounjaro is the most popular. Around 9 out of 10 people getting it do so privately, often through online providers or high-street pharmacies.

What’s changing?

From September, the manufacturer Eli Lilly is putting up the price. The highest dose, which is one of the most commonly used, will increase from around £122 to £330 per month - a rise of around 170%. Lower doses will also cost more, but the increases will be smaller.

These changes only apply to people buying the drug privately and not those getting the medicine on the NHS. NHS prices are agreed in separate deals and will stay the same.

Why is this happening?

Eli Lilly says the current private price in the UK was always temporary. The company initially set it low to help people access the drug earlier. Now that more research is available, and the drug has been launched in more countries, they say the UK price needs to match what other countries pay.

The manufacturer also said the price change was partly influenced by the global debate around medicine costs. In the US, President Donald Trump has suggested linking medicine prices to what’s paid in other countries. Eli Lilly says it supports fair pricing, but does not think that approach works in practice.

What are the alternatives?

Wegovy is a different injectable weight-loss medicine, made by Novo Nordisk. It works in a similar way and is also available on private prescription in the UK. Some people may find it easier to access or afford than Mounjaro, depending on the dose and provider.

Other options include tablets such as orlistat, as well as lifestyle support services offered by the NHS or local councils. Not all treatments work in the same way, and they’re not right for everyone, so it’s important to get proper advice.

What should you do next?

If you’re using Mounjaro and worried about the cost, speak to your doctor or pharmacist. They can help you review your treatment and talk through other options.

Do not stop your injections suddenly without getting medical advice. A sudden stop can cause your blood sugar or appetite to change quickly, which might affect your health.

You can also ask about getting treatment through the NHS. Weight-loss medicines are only offered on the NHS in certain situations, but your doctor can explain whether you might qualify.

NHS England has announced that some people will now be able to get the Mounjaro jab from their doctor or at a local clinic.

This applies to people who have:

  • A BMI of 40 or above - or 37.5 if you are from a minority ethnic group.

  • Four out of five of the following health conditions - type 2 diabetes, high blood pressure, heart disease, high cholesterol, and sleep apnoea.

Patient picks for Health news

What the new generic diabetes and heart medicine means for you: dapagliflozin explained

Health news

What the new generic diabetes and heart medicine means for you: dapagliflozin explained

A major change to one of the NHS’s most widely used diabetes and heart medicines could save hundreds of millions of pounds and make proven treatments more accessible to thousands of patients across the UK. The change centres on dapagliflozin - a medicine used to treat type 2 diabetes, heart failure and certain kidney conditions. It belongs to a family of drugs called SGLT2 inhibitors - sometimes called 'flozins' - which have been described as one of the most important advances in diabetes and heart care in the last decade. Now that the medicine’s patent has been ruled invalid, generic dapagliflozin, identical in safety and effectiveness to the branded version, can be prescribed on the NHS at a much lower cost.

by Thomas Andrew Porteus, MBCS

Influencers are promoting dangerous peptides on social media – and regulators are struggling to keep up

Health news

Influencers are promoting dangerous peptides on social media – and regulators are struggling to keep up

Once confined to niche bodybuilding forums and hardcore gyms, unproven injectable peptides are now being openly marketed online to the average gym-goer by social media influencers – and regulators struggling to keep up. Across Instagram, TikTok or YouTube, unapproved and harmful peptide products are being promoted as shortcuts to fat loss, anti-ageing, health and recovery and muscle growth. Peptides actually occur naturally in our body. They regulate a variety of important functions, including metabolism, appetite, hormone production and tissue repair. Synthetic versions of peptides are also used in some medicines, which are legitimate and have been clinically proven. These include GLP-1s (which are used for weight loss and managing diabetes) and insulin. But a booming, parallel “grey market” now exists online for unapproved peptide compounds. These products are primarily being sold by so-called wellness brands and in influencer-led storefronts. Many of these products are marketed as cutting-edge solutions for optimising health and body enhancement. The problem is that many of these substances have not undergone full clinical safety evaluation and are not approved for human use. Many have also been found to be contaminated with other harmful ingredients. Unapproved injectable peptides therefore pose serious health risks. Some of the risks they may pose00092-0/abstract) include nausea, vomiting, abdominal pain, gastrointestinal issues, headaches and fatigue or weakness. Immune issues, as well as allergic reactions and infections have also been reported. Moreover, there’s a clear lack of rigorous human safety data. Yet these risks often aren’t disclosed by the people selling them.

by Luke Cox

Article history

The information on this page is peer reviewed by qualified clinicians.

Join the conversation

Share your thoughts or experiences with others in our patient communities.

Disclaimer: The views expressed in the community do not represent medical advice. For any health concerns, consult your GP or healthcare provider.
flu eligibility checker

Ask, share, connect.

Browse discussions, ask questions, and share experiences across hundreds of health topics.

symptom checker

Feeling unwell?

Assess your symptoms online for free

Sign up to the Patient newsletter

Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.

Please enter a valid email address

By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.